Skip to main navigation TOP MENU Menu Investors & Media CORPORATE PROFILE ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to “target a better now.” The Company has built a productive platform generating a broad pipeline of ADCs targeting solid tumors and hematologic malignancies. NASDAQ: IMGN $6.44 +1.69 11:22 AM EST on Nov 30, 2021 Data Provided by Refinitiv. Minimum 15 minutes delayed. PRESS RELEASES Nov 30, 2021 ImmunoGen Announces Positive Top-Line Results from Pivotal SORAYA Trial of Mirvetuximab Soravtansine in Ovarian Cancer Read More Nov 24, 2021 ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Read More VIEW MORE EVENTS & WEBCASTS Nov 30, 2021 SORAYA Top-Line Results Conference Call Listen to webcast Learn More Oct 29, 2021 ImmunoGen Third Quarter 2021 Operating Results Conference Call Listen to webcast Learn More VIEW MORE PRESENTATIONS Corporate Presentation – June 2021 SHAREHOLDER INQUIRIES Inquiries related to the Company may be directed to the Investor Relations department at our headquarters. Communications related to stock and transfer requirements, including lost stock certificates and change of name or address, should be directed to the Transfer Agent. CORPORATE HEADQUARTERS ImmunoGen, Inc. 830 Winter Street Waltham, MA 02451-1477 Phone: (781) 895-0600 Email: info@immunogen.com CORPORATE COUNSEL Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. Boston, MA TRANSFER AGENT AND REGISTRAR Broadridge Corporate Issuer Solutions, Inc. P.O. Box 1342 Brentwood, NY 11717 Phone: (877) 830-4936 Fax: (215) 553-5402 E-mail: shareholder@broadridge.com INDEPENDENT ACCOUNTANTS Ernst & Young LLP Boston, MA RECEIVE E-MAIL ALERTS Sign up to receive e-mail alerts whenever ImmunoGen, Inc. posts new information to the site. SIGN UP IMMUNOGEN SHAREHOLDER TOOLS E-MAIL ALERTS RSS FEEDS PRINT EMAIL CONTACT US PRIVACY POLICY USAGE POLICY © 2021 ImmunoGen Inc., All Rights Reserved